CUMBERLAND PHARMACEUTICALS INC 10-Q, filed Nov 13, 2020: IDEA: XBRL DOCUMENT
Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details) - USD ($) |
1 Months Ended | 9 Months Ended | |
|---|---|---|---|
Nov. 30, 2018 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| Business Acquisition [Line Items] | |||
| Payment to acquire business upon closing | $ 0 | $ 5,000,000 | |
| Vibativ | |||
| Business Acquisition [Line Items] | |||
| Payment to acquire business upon closing | $ 20,000,000.0 | 20,000,000 | |
| Cash payment during 2019 | $ 5,000,000.0 | 5,000,000 | |
| Fair value of contingent consideration - net sales royalty | 9,182,000 | ||
| Total consideration | $ 34,182,000 | ||